[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641423":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":27,"locations":12,"responsibleParty":33,"collaborators":35,"id":38,"slug":12,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":39,"sex":45,"minAge":46,"maxAge":12,"enrollmentInfo":47,"targetDuration":12,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":58,"overallStatus":65,"whyStopped":12,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":12},{"fullName":5,"class":6},"Universidade Nova de Lisboa","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard Rehabilitation Care","NO_INTERVENTION","Participants receive standard conservative management consisting of a home-based exercise programme and physical therapy, with longitudinal clinical and imaging follow-up according to the study schedule.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Platelet-Rich Plasma Injection Plus Standard Rehabilitation Care","EXPERIMENTAL","Participants receive percutaneous autologous platelet-rich plasma (PRP) injection in addition to standard conservative management consisting of a home-based exercise programme and physical therapy, with longitudinal clinical and imaging follow-up according to the study schedule.",[18],"Biological: Platelet-Rich Plasma (PRP) Injections",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"BIOLOGICAL","Platelet-Rich Plasma (PRP) Injections","Autologous leucocyte-poor platelet-rich plasma prepared from peripheral blood collected on the day of treatment and administered as a single ultrasound-guided percutaneous injection at or near the partial supraspinatus tendon tear, in addition to standard rehabilitation care. PRP is processed by centrifugation and a residual sample is reserved for cellular and molecular characterization",[14],[26],"Autologous Platelet-Rich Plasma",[28],{"name":29,"role":30,"phone":31,"phoneExt":12,"email":32},"António Proença Caetano, Medical Doctor","CONTACT","00351913746170","aprocaetano@gmail.com",{"type":34,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR",[36],{"name":37,"class":6},"Hospital da Luz, Portugal","100641423",false,"NCT07659600","Platelet-Rich Plasma for Partial Rotator Cuff Tears","Performance of Autologous Platelet-rich Plasma Injection for Tendon Regeneration in Partial Supraspinatus Tears","OPTIMISE","Inclusion Criteria:\n\n* Eligible patients are at least 18 years old, and have clinical (VAS pain score ≥4, loss of \\>25% in ROM, positive in at least one clinical test such as Jobe, Neer, Drop arm, Hawins-Kennedy, Patte) and imaging findings compatible with partial supraspinatus tear, within 3 months of diagnosis.\n* Patients may have undergone conservative treatments, including lifestyle modification, oral analgesics, or physical therapy, with the exception of shoulder injections.\n* Must be willing to provide consent.\n\nExclusion Criteria:\n\n* Patients less than 18 years old\n* Patients with other or concomitant rotator cuff or shoulder muscle\u002Ftendon tear(s), complete tears, SLAP tears ≥ grade 2\n* Patients with auto-immune based joint diseases, osteoarthritis (KL grade ≥ 2), adhesive capsulitis, infection, nerve-related conditions, immunocompromised conditions, malignancy, coagulopathy\n* Patients on antiplatelet, anticoagulant, antitumor or immunosuppressive drugs\n* Uncontrolled diabetes, other systemic disorders (hepatitis, rheumatoid arthritis)\n* Pregnancy\n* Shoulder instability\n* Previous shoulder injection or surgery\n* Unwillingness to provide informed consent","ALL","18 Years",{"count":48,"type":49},100,"ESTIMATED","INTERVENTIONAL",[52],"NA","The goal of this clinical trial is to learn whether platelet-rich plasma (PRP) injection, made from a participant's own blood, can help heal the tendon and improve shoulder symptoms in people with partial tears of the supraspinatus tendon.\n\nThe main questions it aims to answer are:\n\n* Does PRP help the tendon heal?\n* Does PRP improve pain, shoulder movement, daily function, and shoulder magnetic resonance imaging (MRI) findings?\n\nResearchers will compare PRP plus standard of care (physical therapy) to standard of care alone to see if PRP leads to better healing and better clinical results. Researchers will also study if differences in specific biomolecules in PRP are associated with differences in treatment response.\n\nParticipants will:\n\n* receive standard of care treatment, with or without PRP injection depending on the study group\n* have blood collected for PRP preparation\n* have their pain, shoulder movement, and shoulder function assessed\n* undergo shoulder MRI scans\n* be followed over time to measure healing and symptom improvement",[55,56,57],"Partial Supraspinatus Tear","Rotator Cuff Tears (RCTs)","Rotator Cuff Injury",[59,60,61,62,63,64],"Platelet-Rich Plasma","Partial Supraspinatus Tears","Rotator Cuff Tears","Autologous PRP","PRP","Shoulder pain","NOT_YET_RECRUITING","2026-06-15",{"date":68,"type":69},"2026-06-22","ACTUAL",{"date":71,"type":49},"2026-06-01",{"date":73,"type":49},"2029-12-01",{"name":5,"class":6}]